<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>At the University of Pittsburgh, <z:chebi fb="3" ids="49957">xenon</z:chebi>-enhanced computed tomography (XeCT) serves numerous critical roles in the management of patients following aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain>Routine baseline XeCT studies are obtained within 24 hours of surgery and are used for comparison to later studies </plain></SENT>
<SENT sid="2" pm="."><plain>In the setting of a delayed neurological deficit, XeCT is used emergently to distinguish vasospasm from other possible causes and to triage patients to appropriate non-invasive or invasive therapies </plain></SENT>
<SENT sid="3" pm="."><plain>In cases of a delayed neurologic deficit without CBF changes, regardless of transcranial doppler results which can be unreliable, XeCT can prevent unnecessary angiography and potentially harmful invasive treatments </plain></SENT>
<SENT sid="4" pm="."><plain>For patients demonstrating territorial <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> diagnostic of symptomatic vasospasm, XeCT is used to monitor the efficacy of both invasive and non-invasive interventions </plain></SENT>
<SENT sid="5" pm="."><plain>This paper summarizes the results and significance of clinical studies of XeCT in the management of patients after SAH at our institution </plain></SENT>
</text></document>